



RECEIVED


OCT 01 2002

PATENT

#14/c
DmT
10-202

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	McCarthy et al.)	Group Art Unit 1646
)	
Appl. No.	:	09/754,949)	I hereby certify that this correspondence and all
)	marked attachments are being deposited with
Filed	:	January 4, 2001)	the United States Postal Service as first-class
)	mail in an envelope addressed to: United States
For	:	METHODS FOR)	Patent and Trademark Office, P.O. Box 2327,
		IDENTIFYING INHIBITORS)	Arlington, VA 22202, on
		OF NEURONAL)	
		DEGENERATION)	September 23, 2002
)	(Date)
)	
)	Ginger R. Dreger, Reg. No. 33,055
Examiner	:	Olga N. Chernyshev		

AMENDMENT AND RESPONSE TO OFFICE ACTION

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

This is in response to the Office Action, mailed on April 22, 2002 (Paper No. 12), setting a three-months term. Please consider the following amendments and response.

In the specification:

Please replace the paragraph, beginning at page 3, line 4, with the following rewritten paragraph:

--Another protein that may play a role in the neuronal loss in Alzheimer's disease is Par-4. Prostate apoptosis response-4 (Par-4), a protein recently implicated as a mediator of prostate cancer, melanoma, and neuronal cell death, has been found to be elevated in vulnerable regions of the Alzheimer's disease brain (Guo *et al.*, Nature Med., 4:957-962 (1998)). Par-4 expression is also elevated in cultured cells expressing FAD PS1 (Gue *et al.*, *supra*). Inhibition of Par-4 expression or function can prevent neuronal apoptotic cell death induced by β -amyloid or

09/30/2002 AOSMAN1 00000025 09754949

01 FC:116

400.00 OP

C